• Leiomyoma, fibroids, myomen. • Abnormal uteriene bleeding (AUB), hevig menstrueel bloedverlies (HMB). • Angiogenesis, angiogenese.
Conditions
Interventions
The patient will not undergo any specific interventions related to this study other than regular treatment for fibroids or heavy menstrual bleeding. Residual fibroid and endometrial tissue will be col
Sponsors
VU University Medical Centre
Eligibility
Inclusion criteria
Inclusion criteria: • Signed informed consent • > 18 years • Premenopausal • Myomectomy for bleeding disorders • Hysterectomy for bleeding disorders and fibroids • Hysterectomy for non-bleeding disorders (no fibroids)
Exclusion criteria
Exclusion criteria: • Uterine abnormalities (except fibroids) such as endometrial polyps and adenomyosis • deep infiltrating endometriosis, • pelvic inflammatory disease (PID), • previous occlusion or embolization of uterine vessels • malignancy of cervix, endometrium, myometrium or ovary
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Histopathologic study: •Microvascular density (MVD), by the stained CD31/CD34. In vitro study •Time of recovery of HUVEC monolayer confluency, which gives a level of migration index. •Quantity of ATP present, equivalent to the presence of metabolically active HUVEC and consequently the degree of proliferation. •Motility index of HUVEC, which resembles the sprouting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Histopathologic study: • Endothelial proliferation index, as ratio of expression of double stained CD31/CD34 and Ki-67. • The expression of actin (SMA positive vessels), which resemble the mature, pericyte covered vessels. • Difference in absolute number and percentage of pericyte-naked / immature vessels. | — |
Contacts
Public ContactF.A. Groenman
VUMC. 8F-026
Outcome results
None listed